+

WO2007042010A3 - Synergistische pharmazeutische zusammensetzung enthaltend ein peptid mit 2 bis 5 aminosäuren - Google Patents

Synergistische pharmazeutische zusammensetzung enthaltend ein peptid mit 2 bis 5 aminosäuren Download PDF

Info

Publication number
WO2007042010A3
WO2007042010A3 PCT/DE2006/001795 DE2006001795W WO2007042010A3 WO 2007042010 A3 WO2007042010 A3 WO 2007042010A3 DE 2006001795 W DE2006001795 W DE 2006001795W WO 2007042010 A3 WO2007042010 A3 WO 2007042010A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
relates
compositions
peptide
amino acids
Prior art date
Application number
PCT/DE2006/001795
Other languages
English (en)
French (fr)
Other versions
WO2007042010A2 (de
Original Assignee
Goerne Herbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goerne Herbert filed Critical Goerne Herbert
Priority to US12/089,933 priority Critical patent/US20100035824A1/en
Priority to EP06805412A priority patent/EP1986634A2/de
Priority to CA002625661A priority patent/CA2625661A1/en
Priority to AU2006301747A priority patent/AU2006301747B2/en
Priority to JP2008534866A priority patent/JP2009514800A/ja
Publication of WO2007042010A2 publication Critical patent/WO2007042010A2/de
Publication of WO2007042010A3 publication Critical patent/WO2007042010A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fodder In General (AREA)

Abstract

Die vorliegende Erfindung betrifft pharmazeutische Zusammensetzungen zum Verbessern der Verfügbarkeit von Wirkstoffen in Säugetieren. Insbesondere betrifft sie Zusammensetzungen, mit denen die Wirkung von Isoflavonen bzw. Eisen auf Säugetiere unterstützt werden kann. Eine besonders bevorzugte Zusammensetzung ist die Kombination des Isoflavons Genistein mit dem Dipeptid Glu-Glu. Weiterhin gehört zur Erfindung die Verwendung dieser Zusammensetzungen zur Therapie und Prophylaxe von Herz-Kreislauf-Erkrankungen, Erkrankungen im Zusammenhang mit einer erhöhten Thrombozytenaggregation, Stoffwechsel-Erkrankungen, Knochenerkrankungen oder Krebserkrankungen. Desweiteren umfasst die vorliegende Erfindung Verfahren zum Herstellen von Arzneimitteln, insbesondere zur Hemmung der Thrombozytenaggregation, die das Bereitstellen und Mischen von Isoflavonen und negativ geladenen Peptiden umfassen.
PCT/DE2006/001795 2005-10-12 2006-10-10 Synergistische pharmazeutische zusammensetzung enthaltend ein peptid mit 2 bis 5 aminosäuren WO2007042010A2 (de)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US12/089,933 US20100035824A1 (en) 2005-10-12 2006-10-10 Synergistic Pharmaceutical Composition
EP06805412A EP1986634A2 (de) 2005-10-12 2006-10-10 Synergistische pharmazeutische zusammensetzung enthaltend ein peptid mit 2 bis 5 aminosäuren
CA002625661A CA2625661A1 (en) 2005-10-12 2006-10-10 Synergistic pharmaceutical composition containing a peptide with 2 to 5 amino acids
AU2006301747A AU2006301747B2 (en) 2005-10-12 2006-10-10 Synergistic pharmaceutical composition containing a peptide with 2 to 5 amino acids
JP2008534866A JP2009514800A (ja) 2005-10-12 2006-10-10 相乗作用的な薬学的組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005049372.6 2005-10-12
DE102005049372 2005-10-12

Publications (2)

Publication Number Publication Date
WO2007042010A2 WO2007042010A2 (de) 2007-04-19
WO2007042010A3 true WO2007042010A3 (de) 2008-02-21

Family

ID=37762550

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2006/001795 WO2007042010A2 (de) 2005-10-12 2006-10-10 Synergistische pharmazeutische zusammensetzung enthaltend ein peptid mit 2 bis 5 aminosäuren

Country Status (6)

Country Link
US (1) US20100035824A1 (de)
EP (1) EP1986634A2 (de)
JP (1) JP2009514800A (de)
AU (1) AU2006301747B2 (de)
CA (1) CA2625661A1 (de)
WO (1) WO2007042010A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085624A (zh) * 2015-09-21 2015-11-25 艾堪生物科技（天津）有限公司 光滑爪蟾皮肤抗菌肽及其制备方法与用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0621279D0 (en) * 2006-10-26 2006-12-06 Nat Blood Service Binding site
JP5747397B2 (ja) * 2008-02-07 2015-07-15 学校法人近畿大学 医薬組成物
WO2010134226A1 (ja) * 2009-05-20 2010-11-25 学校法人日本大学 タンパク質療法や細胞の分化/未分化制御、抗体療法に応用可能な細胞内でのタンパク質の安定化を可能にする酸性アミノ酸からなるモチーフの確立
WO2012147102A1 (en) * 2011-04-25 2012-11-01 Council Of Scientific & Industrial Research Bioactive fractions and compounds from dalbergia sissoo for the prevention or treatment of osteo-health related disorders
JP2015534951A (ja) * 2012-10-16 2015-12-07 ジェンスペラ，インコーポレイテッド 注射可能な癌組成物
CA3090831A1 (en) * 2018-04-04 2019-10-10 Tasly Pharmaceutical Group Co., Ltd. Pharmaceutical composition and application thereof
KR20240086940A (ko) * 2022-12-09 2024-06-19 (주)케어젠 연골 재생용 펩타이드 및 이의 용도
CN116889573A (zh) * 2023-08-28 2023-10-17 复旦大学附属中山医院 大豆苷在制备抗血小板药物中的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2726755A1 (de) * 1976-06-16 1977-12-22 Rumen Chemie Ag Eisenhaltiger futterzusatz fuer spanferkel
WO1987004622A1 (en) * 1986-02-06 1987-08-13 Albion Laboratories, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
WO2003092674A1 (en) * 2002-05-02 2003-11-13 Integrity Pharmaceutical Corporation Prenatal multivitamin/multimineral supplement
CN1491646A (zh) * 2003-08-21 2004-04-28 广西大学 复合氨基酸亚铁盐补铁剂及其生产方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5506211A (en) * 1994-05-09 1996-04-09 The Uab Research Foundation Genistein for use in inhibiting osteroclasts
US5710129A (en) * 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes
WO2002090380A1 (en) * 2001-04-17 2002-11-14 Sankt-Peterburgskaya Obschestvennaya Organizatsiya 'institut Bioregulyatsii I Gerontologii Czo Ramn' Tetrapeptide stimulating the retinal function and the method of its application
DE10133576A1 (de) * 2001-07-13 2003-01-30 Martin Klingmueller Verwendung von physiologisch aktiven Oligopeptiden zur Stabilisierung des Immunsystems

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2726755A1 (de) * 1976-06-16 1977-12-22 Rumen Chemie Ag Eisenhaltiger futterzusatz fuer spanferkel
WO1987004622A1 (en) * 1986-02-06 1987-08-13 Albion Laboratories, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
WO2003092674A1 (en) * 2002-05-02 2003-11-13 Integrity Pharmaceutical Corporation Prenatal multivitamin/multimineral supplement
CN1491646A (zh) * 2003-08-21 2004-04-28 广西大学 复合氨基酸亚铁盐补铁剂及其生产方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200447, Derwent World Patents Index; Class B04, AN 2004-488524, XP002457715 *
KAZUNAO KONDO ET AL: "Genistein, an isoflavone included in soy, inhibits thrombotic vessel occlusion in the mouse femoral artery and in vitro platelet aggregation", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 455, no. 1, 22 November 2002 (2002-11-22), pages 53 - 57, XP002317911, ISSN: 0014-2999 *
TAPIERO H ET AL: "Iron: Deficiencies and requirements", BIOMEDICINE AND PHARMACOTHERAPY, vol. 55, no. 6, July 2001 (2001-07-01), pages 324 - 332, XP002457735, ISSN: 0753-3322 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105085624A (zh) * 2015-09-21 2015-11-25 艾堪生物科技（天津）有限公司 光滑爪蟾皮肤抗菌肽及其制备方法与用途
CN105085624B (zh) * 2015-09-21 2018-07-10 北京海木集团有限公司 光滑爪蟾皮肤抗菌肽及其制备方法与用途

Also Published As

Publication number Publication date
AU2006301747B2 (en) 2011-11-24
US20100035824A1 (en) 2010-02-11
EP1986634A2 (de) 2008-11-05
CA2625661A1 (en) 2007-04-19
JP2009514800A (ja) 2009-04-09
WO2007042010A2 (de) 2007-04-19
AU2006301747A1 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
WO2007042010A3 (de) Synergistische pharmazeutische zusammensetzung enthaltend ein peptid mit 2 bis 5 aminosäuren
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
WO2005023866A3 (en) Peptides that inhibit complement activation
HK1071066A1 (en) Synergistic association of (-)- gossypol with docetaxel or paclitaxel for cancer treatment
WO2007004869A3 (en) Treatment of tumors
WO2008118017A3 (en) Prame derived peptides and immunogenic compositions comprising these
MXPA05009933A (es) Composiciones que comprenden acidos grasos y aminoacidos.
EP3081214A3 (de) Zellnekrosehemmer
WO2005004818A3 (en) Heterocyclic compounds and their use as anticancer agents
EP2341142A3 (de) HLA-A*1101-beschränktes WT1-Peptid und pharmazeutische Zusammensetzung damit
SI1589987T1 (sl) Uporaba katelicidin ll-37 peptidnih derivatov za uporabo pri zdravljenju kroniäśnih ran
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
MX338338B (es) Composiciones y metodos utiles para el tratamiento de enfermedades respiratorias.
MY143795A (en) Tetrahydropyridoindole derivatives
WO2008011559A3 (en) Synthetic lung surfactant and use thereof
WO2008148873A3 (en) Hydroxyproline compositions and uses thereof
WO2006128022A3 (en) Solid compositions and methods for treating middle-of-the night insomnia
WO2012143364A3 (en) Cosmetic composition for use in increasing collagen synthesis in skin cells
TW200700107A (en) Methods and compositions for preventing and treating aging or photodamaged skin
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
HK1083296A1 (en) Enteral composition for the prevention and/or treatment of sepsis
AU2001264515A1 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
AP2001002377A0 (en) Substituted phenoxyacetic acids.
TW200610535A (en) Methods and compositions for preventing and treating hyperpigmentation of skin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2625661

Country of ref document: CA

Ref document number: 2008534866

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2006301747

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006805412

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006301747

Country of ref document: AU

Date of ref document: 20061010

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006301747

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12089933

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载